Authors: Caruso Michael, Shuttle Shannon, Amelse Lisa, Elkhenany Hoda, Schumacher James, Dhar Madhu S
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Mesenchymal stem cells (MSCs) hold considerable promise for equine wound management due to their paracrine signalling capacity—the ability to secrete bioactive molecules that promote fibroblast activity and tissue remodelling—yet clinical evidence remains limited. Caruso and colleagues investigated whether bone marrow-derived MSCs from a single allogenic donor could enhance cutaneous wound healing through both laboratory and clinical approaches, characterising the cells' properties and testing conditioned medium on human fibroblasts before administering intradermal MSC injections into four horses with full-thickness thoracic wounds over a 30-day monitoring period. In vitro work demonstrated that medium conditioned by proliferating MSCs significantly enhanced human fibroblast migration and proliferation compared with standard culture medium, a promising signal of therapeutic potential; however, this beneficial effect did not manifest in the clinical setting when wounds were assessed via three-dimensional imaging and inflammatory marker expression. Importantly, the allogenic MSCs provoked no detectable immune response in recipient horses, suggesting that immunological rejection is not a barrier to their use and opening the door to off-the-shelf cellular therapies. The authors acknowledge that demonstrating efficacy in vivo may require investigating alternative MSC sources (adipose tissue, umbilical cord blood), higher cell doses, or animal models with compromised healing capacity—findings that should inform the design of future equine regenerative medicine trials before committing to widespread clinical adoption.
Read the full abstract on PubMed
Practical Takeaways
- •While MSC conditioned medium shows promise for fibroblast activation in laboratory settings, direct intradermal MSC injection did not accelerate healing in this small equine trial—larger studies and alternative cell sources are needed before clinical adoption
- •Allogenic MSCs appear immunologically well-tolerated in horses, reducing concerns about rejection when using donor cells from other horses
- •Consider that positive in vitro results may not translate to in vivo efficacy; practitioners should await larger, controlled trials before investing in MSC therapies for routine wound management
Key Findings
- •MSC conditioned medium significantly enhanced human fibroblast proliferation in vitro compared to standard serum-containing medium
- •Allogenic equine bone marrow-derived MSCs did not trigger immunologic rejection when injected intradermally
- •In vivo wound healing effects of intradermally injected MSCs were not detectable in 4 horses over 30 days despite positive in vitro results
- •Molecularly characterized equine MSCs showed typical markers and trilineage differentiation capacity